Modification of simple and specific test for measuring lipid peroxides in plasma

In our paper, we used and recommended an isometric (spectrophotometric) test to measure lipid peroxides in human plasma samples. The use of a commercially available colour reagent (CHO-iodide; Merck, Germany) made the technique very simple and easy to use.

Not long after the paper had been published, we and others have had difficulties performing the test as it was described. Basically, the saline treated (control) sample resulted in higher absorbance than the colour reagent (potato) sample. This was due to some as yet unidentified changes in the CHO-iodide reagent. The colour reagent presently available somehow quenches the original absorbance of plasma due to yellowish carotenoids. All our efforts to identify and eliminate this interference or change the protocol while measuring the formed I₂ at 360nm have failed.

We therefore adapted a technique, which measures iodine in the presence of starch as a blue colour iodine-starch complex at 560nm, where the natural yellowish colour of plasma does not interfere with the measurement. This modification has been in use for six months with different batches of CHO-iodide and produced reliable estimate of the overall oxidative capacity of plasma.

Reagents:
CHO-iodide (Merck, Germany).
Butylated hydroxy tolune (BHT): 0.572 mg/ml in ethanol.
Sodium thiosulphate solution from Sigma, No. S-2630: A 1% solution is made freshly in 0.7 M sodium chloride (39.2 mg/100 ml) by immersing into boiling water for a few minutes. After centrifugation (3 minutes at 12 000 rpm, Eppendorf centrifuge), the clear supernatant fluid is used the same day.

Procedure: Blood is taken into EDTA (1.5 mg/ml), centrifuged, and the plasma samples kept at 4°C for no longer than two days. In a small phial, place 200 µl plasma, 1 ml colour reagent (CHOD), 10 µl BHT and 200 µl starch solution. Mix and transfer into a disposable cuvette and read the absorbance immediately at 560 nm against distilled water. Place the cuvette immediately into dark and then read the absorbance again at 60 minutes. The difference in the absorbance represents the peroxide content of plasma. Direct calculation by using molar absorbivity is difficult due to the variation of the absorption with the source of starch. However, for one batch, the system can be calibrated by hydrogen peroxide, according to the stoichiometry of the reaction:

\[(H_2O_2 + 2I^- + 2H^+ \rightarrow I_2 + H_2O)\]

Absorption changes are linear between the amounts of peroxide added (0.2-1 nmol) and the I₂ produced.


Parathyroid hormone related protein (PTHrP) in hypercalcaemia of lymphoproliferative disease

Bolo-Deoku et al have shown that PTHrP was not implicated in a case of hypercalcaemia in Hodgkin's disease, thus expanding the very limited literature on PTHrP in lymphoproliferative disorders of the same case of hypercalcaemia in chronic lymphocytic leukaemia (CLL) where the same conclusion was reached.

Eight years after presentation, a patient with IV/IV C-B-CLL developed acute severe low back pain due to vertebral body collapse. Generalised loss of bone density was apparent radiologically, but no discreet osteolytic lesion were found. Corrected serum calcium concentration was 2.94 mmol/l (range 2.26-2.60), phosphate activity 1.31 mmol/l (range 0.8-1.4), alkaline phosphatase 84 IU/l (range 30-115), and renal function was normal. Vigorous intravenous hydration and intensified treatment with corticosteroids failed to control the hypercalcaemia and a peak corrected serum calcium of 3.29 mmol/l was reached before effective treatment with pamidronate sodium was started. Prolymphocytoid transformation and myeloma were excluded and there was no evidence of coincidental malignancy. Serum 25-hydroxyvitamin D was 11.9 ng/ml (range 8-50), PTH 1.7 pg/ml (range 0.9-5.4), and PTH-related protein (PTHRP) was less than 0.23 pmol/l (normal).

While lymphomatous (tumour necrosis factor β), interlukins 1 and 6, and prosta- glandins have a well defined role in the bone disease of myelomatosis, the mechanisms underlying dysfunctional osteoclast activity in other lymphoproliferative disorders are unknown. Although larger studies must be performed, it seems unlikely that PTHrP has an important role.

*SV Davies 1WORA
*CAJ Wardrop 2Departments of "Haematology and Medicine, University of Wales, College of Medicine, Cardiff CF4 4XY


Value of PCNA and Ki67 staining in breast cancer

The failure of PCNA to reflect proliferative activity, as measured by Ki67 or mitotic counting in breast tumours, documented by Leonardi and colleagues, is disappointing. We have found a weak positive correlation between PCNA staining and Ki67 staining in both benign and malignant breast tumours (personal observation).

To some degree such observations may be related to the techniques used. Our practice with both Ki67 and PCNA is to count areas of highest antigen expression after scanning the slide at low magnification. This gives a measure of the maximum proliferative activity in any given tumour and obviates the need to decide how many areas are to be used for high concentration to include (not to mention the intermediate areas).

Using this method, we found no correlation between PCNA and mitotic count in breast cancer. A weak correlation when assessing PCNA expression that mitotic figures are frequently uncounted. This is consistent with its described expression in the S-phase under optimal conditions. Yet PCNA expression is frequently higher than Ki67 index as we have found, and higher than thymidine labelling in benign breast tissue. As Ki67 and thymidine labelling are restricted to the cell population, PCNA must therefore persist in non-cycling cells but in a variable manner, losing its association with mitotic activity and making its correlation with Ki67 expression tenuous.

This suggests that although PCNA is to some extent comparable with Ki67 it is influenced by factors as yet undefined to such an extent that it loses its usefulness in quantifying proliferative activity.

RP SULLIVAN
Department of Pathology, University College Hospital, Galway, Republic of Ireland


Dr Barbaraeis comments:

Dr Sullivan's letter, which suggests a weak correlation between PCNA and Ki67 immunostaining in benign and malignant breast tumours, agrees with our paper where we concluded that in breast cancer PCNA immunostaining is not a substitute for Ki67.